New research indicates that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who stop conventional diet and exercise plans.
Research printed in a prominent medical journal demonstrates that while obese people can lose a large proportion of their total mass while on the medication, the weight is regained at an estimated rate of nearly a kilo each month after stopping.
"Users purchasing these drugs must be aware of the potential of quick weight regain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
That rate of recovery means a reversion to pre-treatment weight in about 18 months.
Weighing Therapies
The study, which looked at dozens of studies involving thousands of participants, contrasted the outcomes of these new drugs with older methods.
Scientists note that individuals who shed pounds through lifestyle changes alone usually experience a less rapid weight regain—approximately 100 grams monthly—post-intervention.
Explaining the Fast Rebound
Experts propose the way of the jabs explains the amplified weight return.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing the hormone levels several times higher than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' leads to hunger is uncontrolled, making binge eating a significant risk."
A Lifelong Condition?
The NHS suggest the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians say that, considering the likelihood of relapse, the treatment should be considered life-long.
This view is reinforced by drug manufacturers, who say that the findings "highlight the long-term nature of obesity," similar to managing diseases like high blood pressure.
User Testimonies
Individuals who have stopped the jabs describe a powerful resurgence of hunger.
"It felt as if a trigger activating and I was suddenly extremely hungry," recalled an individual.
The struggle is worsened if individuals have not developed permanent dietary or behavioural modifications during therapy.
Widespread Use
Recent estimates suggest that millions of people in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Use is more common among females than men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
Ultimately, researchers stress that while GLP-1 drugs are effective agents for weight loss, they are not a standalone cure and maintained weight loss likely depends on integrated lifestyle support.
